The combination of neratinib and capecitabine in the TBCRC 022 Trial (NCT01494662) showed intracranial action in brain metastases of HER2-positive breast cancer, suggesting the possibility of bilateral HER2 pathway inhibition in resistant scenarios[242]. This evidence concerns the gene ERBB2 and breast carcinoma.